Seastar Medical Holding Corp quarterly report, Q3 FY2021

Filing identity and reporting period

Important identity mismatch: The supplied filing is LMF Acquisition Opportunities, Inc.’s Form 10-Q for the quarter ended September 30, 2021—not a Seastar Medical Holding Corp. filing. This summary reflects the filing provided.

LMF was a special purpose acquisition company (SPAC) formed to pursue a business combination. It had not begun operations, selected a target, or started substantive target discussions as of September 30, 2021.

Financial results and liquidity

At September 30, 2021, total assets were $106.2 million, including $105.6 million in the trust account and $165,840 in unrestricted cash. Current liabilities were $277,306; total liabilities were $11.3 million, including $7.4 million of warrant liabilities and $3.6 million of deferred underwriting commissions. Public shares subject to possible redemption were presented as $105.6 million of temporary equity. The filing reports negative stockholders’ equity of $10.7 million.

For the first nine months, operating cash use was $372,705. The company placed $105.6 million into the trust account and reported $106.1 million of net cash provided by financing activities. The filing provides no operating margin measure; as a pre-combination SPAC, it had no operating revenue.

Material changes and unusual items

• The company reclassified public and private placement warrants as derivative liabilities rather than equity and remeasured them at fair value each reporting period. The resulting non-cash gain materially affected reported earnings; the quarter’s net income did not arise from operating activity.
• The company also revised presentation of all public shares subject to redemption as temporary equity and revised its earnings-per-share allocation. The notes state these presentation changes did not change total assets, liabilities, or operating results.
• The filing describes prior-period financial statement revisions and identifies a material weakness in internal control. Its discussion of whether prior misstatements were material is not fully consistent across sections; investors should review the restatement disclosures and control discussion directly.

Outlook, risks and contingencies

The company had no selected business-combination target and reported no operating forecast or guidance. It stated that it generally had 18 months from the January 2021 IPO to complete a combination, with a possible extension to 21 months subject to sponsor funding. The filing contains inconsistent deadline descriptions in different passages, including a note referencing 15 months; verify the controlling charter and offering documents.

Management cited risks to completing a transaction, including COVID-19-related disruption, availability of additional financing, target-search and negotiation challenges, and potential claims against trust funds. It also warned that warrant fair-value changes may create earnings volatility. Disclosure controls were deemed ineffective as of September 30, 2021, due to inadequate segregation of accounting duties and controls over complex financial instruments; management identified these as material weaknesses. No material litigation or off-balance-sheet arrangements were reported.

Investor verification priorities

• Confirm the filing’s registrant: it is LMF Acquisition Opportunities, Inc., not Seastar Medical Holding Corp.
• Review the warrant and redeemable-share accounting revisions, including the inconsistent materiality statements and their implications for comparability.
• Verify the business-combination deadline and any extension terms against the charter, prospectus, and subsequent filings.
• Assess unrestricted cash available for expenses separately from trust assets, which are restricted pending a business combination or redemption.
• Check subsequent filings for target developments, remediation of internal-control weaknesses, and any further SEC or Nasdaq inquiries.